Biogen Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for BIIB, updated each market day.
BIIB AI Sentiment
AI sees no strong directional signal for Biogen Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Biogen Inc. Common Stock
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Sector
Exchange
Market Cap
$25,992,402,894
Cap Tier
Employees
7,500
Headquarters
CAMBRIDGE, MA
Listed Since
Sept. 17, 1991
Website
BIIB Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
BIIB Volatility
Biogen Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
